Synergistic Inhibitory Effect of GQDs–Tramiprosate Covalent Binding on Amyloid Aggregation
Abstract
Inhibiting the amyloid aggregation is considered to be an effective strategy to explore possible treatment of amyloid-related diseases including Alzheimer's disease, Parkinson's disease, and type II diabetes. Herein, a new high-efficiency and low-cytotoxicity Aβ aggregation inhibitors, GQD-T, was designed through the combination of two Aβ aggregation inhibitors, graphene quantum dots (GQDs) and tramiprosate. GQD-T showed the capability of efficiently inhibiting the aggregation of Aβ peptides and rescuing Aβ-induced cytotoxicity due to the synergistic effect of the GQDs and tramiprosate. In addition, the GQD-T has the characteristics of low toxicity and great biocompatibility. It is believed that GQD-T may be a potential candidate for an Alzheimer's drug and this work provides a new strategy for exploring Aβ peptide aggregation inhibitors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
QDs possess stable fluorescence, allowing imaging of amyloid aggregates; tramiprosate inhibits Aβ aggregation, acting on different parts of the pathological cascade.
“The QD themselves possess stable fluorescence, which allows them to be used for imaging amyloid aggregates. Tramiprosate, in turn, inhibits Aβ aggregation, acting on different parts of the pathological cascade.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [87]
The pharmacokinetics of the graphene QD-tramiprosate system is determined by the nanocarrier, which ensures delivery of both components across the BBB and their joint accumulation in the target area.
“The pharmacokinetics of such a system is determined by the nanocarrier, which ensures the delivery of both components across the BBB and their joint accumulation in the target area [87].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [87]
The first approach-combining functions in a single agent-is implemented in systems based on graphene QDs conjugated with tramiprosate.
“The first approach—combining functions in a single agent—is implemented, in particular, in systems based on graphene QDs conjugated with tramiprosate.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [87]
Cites
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · see citing works
Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136 · see citing works
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64 · see citing works
Wang, W., Liu, M., Gao, W., Sun, Y., & Dong, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c17267 · Cited by 53 · see citing works
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1 · see citing works
“The pharmacokinetics of such a system is determined by the nanocarrier, which ensures the delivery of both components across the BBB and their joint accumulation in the target area [87].”
- Authors
- Liu, Y., Xu, L.-P., Wang, Q., Yang, B., & Zhang, X.
- Affiliations
- Huanghe Science and Technology College (CN)
- Research Center for Bioengineering and Sensing Technology, University of Science & Technology Beijing, Beijing 100083, P.R. China
- Chinese Academy of Sciences (CN)
- University of Science and Technology Beijing (CN)
- Corresponding author
- Yang, Baocheng
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-12-15
- Volume
- 9
- Issue
- 4
- Pages
- 817-823
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2775268498
- Cited by
- 58
- References
- 2
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 3 · 2018: 5
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (21475009, 21475008)
- Beijing Municipal Science and Technology Commission (Z161100000116037)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Materials Chemistry › Carbon and Quantum Dots Applications
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- graphene quantum dots, tramiprosate, amyloid aggregation inhibition, amyloid-beta, Alzheimer's disease, synergistic inhibition, covalent binding, cytotoxicity, biocompatibility, amyloidosis
- MeSH terms
- Alzheimer Disease, Amyloidosis, Diabetes Mellitus, Type 2, Graphite, Humans, Peptide Fragments, Taurine, Amyloid beta-Peptides, Quantum Dots, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
